Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + XELOX in AFP-elevated Gastric Cancer
NCT04098796Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by China Medical University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04098796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098796.